Changes in the Dentate Gyrus Gene Expression Profile Induced by Levetiracetam Treatment in Rats with Mesial Temporal Lobe Epilepsy

Veronica Diaz-Villegas,Luz Adriana Pichardo-Macías,Sergio Juárez-Méndez,Iván Ignacio-Mejía,Noemí Cárdenas-Rodríguez,Marco Antonio Vargas-Hernández,Julieta Griselda Mendoza-Torreblanca,Sergio R. Zamudio

DOI: https://doi.org/10.3390/ijms25031690

IF: 5.6

2024-01-31

International Journal of Molecular Sciences

Abstract:Temporal lobe epilepsy (TLE) is one of the most common forms of focal epilepsy. Levetiracetam (LEV) is an antiepileptic drug whose mechanism of action at the genetic level has not been fully described. Therefore, the aim of the present work was to evaluate the relevant gene expression changes in the dentate gyrus (DG) of LEV-treated rats with pilocarpine-induced TLE. Whole-transcriptome microarrays were used to obtain the differential genetic profiles of control (CTRL), epileptic (EPI), and EPI rats treated for one week with LEV (EPI + LEV). Quantitative RT–qPCR was used to evaluate the RNA levels of the genes of interest. According to the results of the EPI vs. CTRL analysis, 685 genes were differentially expressed, 355 of which were underexpressed and 330 of which were overexpressed. According to the analysis of the EPI + LEV vs. EPI groups, 675 genes were differentially expressed, 477 of which were downregulated and 198 of which were upregulated. A total of 94 genes whose expression was altered by epilepsy and modified by LEV were identified. The RT–qPCR confirmed that LEV treatment reversed the increased expression of Hgf mRNA and decreased the expression of the Efcab1, Adam8, Slc24a1, and Serpinb1a genes in the DG. These results indicate that LEV could be involved in nonclassical mechanisms involved in Ca2+ homeostasis and the regulation of the mTOR pathway through Efcab1, Hgf, SLC24a1, Adam8, and Serpinb1a, contributing to reduced hyperexcitability in TLE patients.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the effect of levetiracetam (LEV) treatment on the gene expression profile of the hippocampal dentate gyrus (DG), especially in the rat model of mesial temporal lobe epilepsy (TLE) induced by pilocarpine. Although levetiracetam is a widely - used antiepileptic drug, its mechanism of action at the gene level has not been fully elucidated. Therefore, the main objective of the study is to identify relevant gene expression changes in the DG of TLE rats through whole - transcriptome microarray analysis and to evaluate the effect of sub - chronic levetiracetam treatment on these changes.

Specifically, the researchers hope to solve the problem through the following points:
1. **Identify gene expression changes**: Use whole - transcriptome microarray analysis to determine the differential gene expression profiles among the control group (CTRL), the epilepsy group (EPI), and the levetiracetam - treated epilepsy group (EPI + LEV).
2. **Verify the expression of key genes**: Verify the RNA levels of key genes by quantitative RT - qPCR technology to confirm the results of microarray analysis.
3. **Explore potential mechanisms**: Explore the possible mechanism of action of levetiracetam, especially non - classical mechanisms related to calcium homeostasis and the mTOR pathway, by analyzing the functions and pathways of differentially expressed genes.

The research results show that levetiracetam treatment can reverse the abnormal expression of certain genes, such as the over - expression of Hgf mRNA and the low - expression of Efcab1, Adam8, Slc24a1 and Serpinb1a genes. These findings suggest that levetiracetam may be involved in non - classical calcium homeostasis and mTOR pathway regulation by regulating the expression of these genes, thereby reducing neuronal hyperexcitability in TLE patients.